FDA: anti-counterfeiting successes are 'drop in the bucket'; Pfizer sells PR plant to Mexico's Neolpharma;

> The FDA says its anti-counterfeiting successes are just "a drop in the bucket." Report

> Mylan ($MYL) is buying an oncology drug production plant in India for $32.5 million. Article

> Pfizer ($PFE) has sold one of the Puerto Rico plants it earmarked for closure to Mexican drugmaker Neolpharma. Article

> Biostar Pharmaceuticals has inked a $3 million deal to manufacture drugs for a Chinese hospital. Article

> The cost of many medicines in Ireland are to drop 10% after the government struck a deal with manufacturers. Article

> Tris Pharma has leased a New Jersey warehouse to accommodate a spike in manufacturing activity. Article

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.